# TABLE OF CONTENTS

I. INTRODUCTION............................................................................................................. 1  
II. BACKGROUND .................................................................................................................. 2  
III. GENERAL CONCEPTS IN METABOLITE SAFETY TESTING................................. 3  
   A. General Approaches for Assessing Metabolite Safety .............................................. 4  
   B. Identification of Metabolites .................................................................................... 5  
   C. General Considerations for Nonclinical Study Design .......................................... 5  
IV. RECOMMENDED STUDIES FOR ASSESSING THE SAFETY OF METABOLITES......................................................................................................................... 6  
   A. General Toxicity Studies .......................................................................................... 6  
   B. Genotoxicity Studies .................................................................................................. 6  
   C. Embryo-Fetal Development Toxicity Studies ............................................................ 6  
   D. Carcinogenicity Studies ............................................................................................ 7  
V. TIMING OF SAFETY ASSESSMENTS........................................................................ 7  
GLOSSARY.................................................................................................................................. 8  
APPENDIX A: DECISION TREE FLOW DIAGRAM......................................................... 9  
APPENDIX B: CASE EXAMPLES OF DRUG METABOLITES ....................................... 10
Safety Testing of Drug Metabolites
Guidance for Industry

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA office responsible for this guidance as listed on the title page.

I. INTRODUCTION

This guidance provides recommendations to industry on when and how to identify and characterize drug metabolites whose nonclinical toxicity needs to be evaluated. Drug metabolites may need to be determined in nonclinical studies when they are disproportionate drug metabolites, that is, metabolites identified only in humans or present at higher plasma concentrations in humans than in any of the animal species used during standard nonclinical toxicology testing.\(^2\)

This guidance applies to small molecule nonbiologic drug products. This guidance does not apply to some cancer therapies.\(^3\)

This guidance supersedes the guidance of the same name published in November 2016. The guidance has been revised to align with the ICH guidance for industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (January 2010).

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only

---

\(^1\) This guidance has been prepared by the Pharmacokinetic Subcommittee of the Pharmacology and Toxicology Coordinating Committee in the Center for Drug Evaluation and Research at the Food and Drug Administration. You may submit comments on this guidance at any time. Submit comments to Docket No. FDA-2008-D-0065 (available at https://www.regulations.gov/docket?D=FDA-2008-D-0065). See the instructions in that docket for submitting comments on this and other Level 2 guidances.

\(^2\) See the Glossary for the definition of disproportionate drug metabolite.

\(^3\) See the ICH guidance for industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals (March 2010) for the safety testing of drug metabolites in cancer therapies. We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/regulatory-information/search-fda-guidance-documents.
II. BACKGROUND

Nonclinical evaluation of drug safety usually consists of standard animal toxicology studies. These studies usually include assessing drug exposure, primarily parent drug plasma concentration. Generally, drug plasma concentration and systemic exposure in the nonclinical studies are compared with systemic exposure in humans to assess the potential risks suggested by nonclinical findings and guide monitoring in clinical trials. This testing paradigm usually is sufficient when the metabolic profile in humans is similar to that in at least one of the animal species used in nonclinical studies, but metabolic profiles can vary across species both quantitatively and qualitatively, and there are cases for which clinically relevant metabolites have not been identified or adequately evaluated during nonclinical safety studies. This situation can occur if the metabolite is formed only in humans and is absent in the animal test species or if the metabolite is present at higher levels in humans than in the animal species used in the standard toxicology testing with the parent drug. Such a metabolite is called a disproportionate drug metabolite.

It is not standard practice for drug metabolites to be evaluated separately in a cross-species safety assessment. As a result, their specific contribution to the overall toxicity of the parent drug has often remained unknown. This lack of understanding about the role of metabolites in drug toxicity may partly reflect the inadequate sensitivity of the analytical methods used to detect and characterize metabolites derived from the parent drug. Technological advances, however, have greatly improved the analytical abilities to detect, identify, and characterize metabolites and may allow a better understanding of the role metabolites play in drug safety assessment.

Drugs entering the body undergo biotransformation via phase 1 and phase 2 metabolic pathways. Based on the nature of the chemical reactions involved, metabolites formed from phase 1 reactions are more likely to be chemically reactive or pharmacologically active and, therefore, more likely to need safety evaluation. A pharmacologically active metabolite may bind to the therapeutic target receptors or other receptors, interact with other targets (e.g., enzymes, proteins), and cause unintended effects. This is a particularly important problem when such a metabolite is formed in humans and not in animals, but the occurrence of a metabolite only in humans and not in any animal test species is rare. A more common situation is the formation of a metabolite at higher levels in humans than in the animal species used in safety testing of the parent drug. This stems from qualitative and/or quantitative differences in metabolic profiles between humans and animals. If at least one animal test species forms this drug metabolite at adequate exposure levels (approximately equal to or greater than human exposure), as

---

4 See the ICH guidances for industry S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (July 1997) and S7A Safety Pharmacology Studies for Human Pharmaceuticals (July 2001).
determined during toxicology testing of the parent drug, it can be concluded that the metabolite’s contribution to the overall toxicity assessment has been established.\(^5\)

Metabolites that form chemically reactive intermediates can be difficult to detect and measure because of their short half-lives. In some cases, however, they can form stable products (e.g., glutathione conjugates) that can be measured. Phase 2 conjugation reactions generally render a compound more water soluble and pharmacologically inactive, thereby eliminating the need for further evaluation. However, if the conjugate forms a potentially toxic compound such as acyl glucuronide, additional safety assessment may be needed.\(^6\)

Since general toxicity studies are designed to assess both target and off-target toxicity of the drug, demonstrating that a metabolite is pharmacologically inactive at the target receptor (or even that it does not meaningfully bind to a receptor or enzyme in a screening test) is not sufficient to ensure that the metabolite is not toxic. Therefore, it may need to be tested in nonclinical toxicity studies.\(^7\)

### III. GENERAL CONCEPTS IN METABOLITE SAFETY TESTING

We encourage identifying any differences in drug metabolism between animals used in nonclinical safety assessments and humans as early as possible during the drug development process.\(^8\) Discovering such differences in drug metabolites late in drug development can cause development delays.

Generally, metabolites identified only in human plasma or metabolites present at higher levels in humans than in any of the animal test species should be considered for safety assessment. Such metabolites are called disproportionate drug metabolites. Human metabolites that can raise a safety concern are those present at greater than 10 percent of total drug-related exposure at steady state.\(^9\)

---

\(^5\) See Appendix A: Decision Tree Flow Diagram. This diagram describes which studies may be needed to determine safety of the drug metabolite.


\(^7\) See Appendix B: Case Examples of Drug Metabolites.


\(^9\) Exposure should be at steady state unless there is some justification for a different measure of exposure. Comparison between human and animal exposure generally is based on area under the curve, but sometimes it may be more appropriate to use C\(_{\text{max}}\). See ICH M3(R2).
The choice of a level of greater than 10 percent for characterization of drug metabolites reflects consistency with FDA\textsuperscript{10} and Environmental Protection Agency guidances.\textsuperscript{11}

A. General Approaches for Assessing Metabolite Safety

A metabolite identified in animals that is not present in humans can mean that a toxicity observed in that animal species, and that can be attributed to the metabolite, may not be relevant to humans. Conversely, a drug metabolite identified during clinical development that is not present in animal test species or is present at much lower levels in animals than in humans can suggest the need for further studies in animals to determine the potential toxicity of the metabolite. In such cases, sponsors can consider two approaches to assessing the effect of the drug metabolite. The first approach is to identify an animal species routinely used in toxicity studies that forms the metabolite at adequate exposure levels (equivalent to or greater than the human exposure), and then investigate the drug’s toxicity in that species. The second approach, if a relevant animal species that forms the metabolite cannot be identified, is to synthesize the drug metabolite and directly administer it to the animal for further safety evaluation. In this approach, analytical methods that are capable of identifying and measuring the levels of the metabolite in the nonclinical toxicity studies should be developed.

We acknowledge the difficulties associated with synthesizing a specific metabolite as well as the inherent complexities that accompany its direct administration. Direct dosing of a metabolite to animals may lead to subsequent metabolism that may not reflect the clinical situation and thus may complicate the toxicity evaluation. Moreover, new and different toxicities may arise from administration of the metabolite that were not observed with the parent drug. However, notwithstanding these possible complications, identifying and evaluating the potential toxicity of the drug metabolite is considered important to ensure clinical safety, and the decision to conduct direct safety testing of a metabolite should be based on a comprehensive evaluation of the data on the parent drug and any information available for the metabolite.

Appendix B provides three case examples when drug metabolites were formed at higher levels in humans than in test animals used in the nonclinical studies and how the safety evaluation was approached. In Case 1, testing the drug metabolite was not needed because the metabolite was adequately characterized in nonclinical toxicity studies with the parent drug. However, in Cases 2 and 3, the drug metabolites had to be tested in toxicity studies by direct administration to the

\textsuperscript{10} See the Veterinary International Conference on Harmonization guidances for industry GL46 Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (MRK) (September 2011) and GL47 Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Comparative Metabolism Studies in Laboratory Animals (September 2011) available on the Veterinary International Conference on Harmonization (VICH) Guidance Documents web page at https://www.fda.gov/animal-veterinary/guidance-industry/veterinary-international-conference-harmonization-vich-guidance-documents.

animal. In Case 3, the drug metabolite was pharmacologically inactive at the therapeutic target receptor but showed a unique toxicity not observed with the parent molecule.

B. Identification of Metabolites

Sponsors should identify the metabolic profile of the drug during the drug development process. This identification can be accomplished at different stages of development using in vitro and in vivo methods. In vitro studies can use liver microsomes, liver slices, or hepatocytes from animals and humans; these studies should generally be conducted before initiating clinical trials. In vivo metabolism study results in nonclinical test species generally should be available early in drug development, and their results will either confirm the results obtained from the in vitro studies or reveal quantitative and/or qualitative differences in metabolism across species. It is the latter situation that may pose a safety concern. Usually, sponsors have conducted human in vivo metabolism studies relatively later in drug development, but we strongly recommend that sponsors conduct in vivo metabolic evaluation in humans as early as feasible.

The adequacy of exposure to drug metabolites that are present at lower levels in animals used in nonclinical studies is determined on a case-by-case basis. Generally, systemic exposure is assessed by measuring the concentration of the parent drug at steady state in serum or plasma. However, when measurements cannot be made in plasma of the test species for any reason, adequate exposure can be verified in other biological matrices such as urine, feces, or bile. We encourage sponsors to contact the FDA early in drug development to discuss these issues.

C. General Considerations for Nonclinical Study Design

When designing a nonclinical study for a disproportionate drug metabolite, one should consider the following factors:

- Similarity of the metabolite to the parent molecule
- Pharmacological or chemical class
- Solubility
- Stability in stomach pH
- Phase 1 versus phase 2 metabolite
- Relative amounts detected in humans versus the amounts detected in animals

Additional factors to be considered include the proposed drug indication and patient population (e.g., nonclinical studies can be abbreviated for serious indications such as amyotrophic lateral

---

12 Although the drug metabolite of toxicological concern usually is one circulating in plasma at greater than 10 percent of total drug-related exposure, other metabolites also can elicit safety concern. For example, a drug metabolite representing greater than 10 percent of urinary excretion relative to the bioavailable dose, or a human fecal metabolite in cases where biliary elimination is the predominant route of excretion in humans, may reflect potential localized renal or bile duct toxicity, respectively. The sponsor should discuss with the appropriate FDA review division the need for further characterization in these instances, which are addressed on a case-by-case basis.

sclerosis), the proposed duration of use (short term, intermittent use, chronic), and the levels of exposure at the therapeutic dose.

IV. RECOMMENDED STUDIES FOR ASSESSING THE SAFETY OF METABOLITES

Good laboratory practice guidelines apply to the nonclinical studies with the drug metabolite designed to evaluate safety (21 CFR part 58). Sponsors may need to conduct the following studies to assess the safety of the disproportionate drug metabolite.

A. General Toxicity Studies

The potential toxicity of a disproportionate drug metabolite should be evaluated to enable comparisons between the metabolite and its parent drug. The duration of the general toxicity study with direct dosing of the metabolite should follow the recommendations listed in ICH M3(R2). Sponsors should investigate the toxicity of the drug metabolite at multiples of the human exposure or at least at levels comparable to those measured in humans. We also recommend using the parent drug’s intended clinical route of administration. However, with justification, one can use other routes to achieve sufficient exposure to the disproportionate metabolite. If the clinical route is oral, it is important to verify the stability of the metabolite in the stomach environment. It is crucial to gather toxicokinetic data from this type of study to ensure adequate exposure.

B. Genotoxicity Studies

The potential genotoxicity of the drug metabolite should be assessed in an in vitro assay that detects point mutations and in another assay that detects chromosomal aberrations. It is important that these assays be conducted according to the recommendations in the ICH guidance for industry S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use (June 2012). If one or both of the in vitro tests are equivocal and/or positive, results from a complete standard battery of genotoxicity studies may be needed.

C. Embryo-Fetal Development Toxicity Studies

When a drug is intended for use in a population that includes women of childbearing potential, sponsors should conduct embryo-fetal development toxicity studies with the drug metabolite. We may ask for other reproductive toxicity studies on a case-by-case basis, depending on results of the general toxicity and embryo-fetal development studies. Sponsors should conduct reproductive toxicity studies in accordance with the ICH guidances on reproductive toxicity. Sometimes the conduct of an embryo-fetal development toxicity study in only one species that forms the drug metabolite can be justified.
D. Carcinogenicity Studies

Carcinogenicity studies should be conducted on metabolites of drugs that are administered continuously for at least 6 months or that are used intermittently to treat chronic or recurrent conditions when the carcinogenic potential of the metabolite cannot be adequately evaluated from carcinogenicity studies conducted with the parent drug. Sponsors should conduct a single carcinogenicity study or an alternative bioassay in accordance with the ICH guidances for industry SIA The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals (March 1996), SIB Testing for Carcinogenicity of Pharmaceuticals (July 1997), and SIC(R2) Dose Selection for Carcinogenicity Studies (September 2008).

V. TIMING OF SAFETY ASSESSMENTS

Early identification of disproportionate drug metabolites can provide clear justification for nonclinical testing in animals, assist in interpreting and planning clinical studies, and prevent delays in drug development. If toxicity studies of a drug metabolite are warranted, sponsors should complete studies and provide study reports to the FDA before beginning large-scale clinical trials.

To optimize and expedite drug development for serious or life-threatening diseases other than cancer (e.g., amyotrophic lateral sclerosis, stroke, human immunodeficiency virus), the number and type of nonclinical studies for the drug metabolites can be modified on a case-by-case basis for those drugs with major beneficial therapeutic advances and for drugs for illnesses that lack an approved effective therapy. Sponsors should contact the appropriate review division to discuss such situations.
**Contains Nonbinding Recommendations**

**GLOSSARY**

_Disproportionate drug metabolite_ — A metabolite present only in humans or present at higher plasma concentrations in humans than in the animals used in nonclinical studies. In general, these metabolites are of interest if they account for plasma levels greater than 10 percent of total drug-related exposure, measured as area under the curve at steady state.

_Metabolite_ — A compound derived from the parent drug through phase 1 and/or phase 2 metabolic pathways.

_Pharmacologically active metabolite_ — A metabolite that has pharmacological activity at the target receptor. The activity may be greater than, equal to, or less than that of the parent drug.
APPENDIX A: DECISION TREE FLOW DIAGRAM

Disproportionate Drug Metabolite

≤10% of total drug-related exposure (area under the curve)

No further testing needed to evaluate metabolite

>10% of total drug-related exposure (area under the curve)

Formed in any animal test species?

Yes

How much?

Exposure in animal studies does approach human exposure

No further testing needed to qualify metabolite

Exposure in animal studies does not approach human exposure

Nonclinical testing with the drug metabolite
APPENDIX B: CASE EXAMPLES OF DRUG METABOLITES

Case 1.
From an initial mass balance study, a metabolite represented 1 to 2 percent of total radioactive dose in rat plasma, 5 percent in dogs, and 20 percent in humans (radioactivity of this metabolite in urine and/or feces was minimal). Based on the up-to-20-fold greater exposure in humans than in animals, nonclinical safety testing was recommended. However, the data generated in the general toxicology studies with the parent drug in the rat and dog suggested that the maximum doses tested produced metabolite exposures that represented at least the therapeutic exposure at the maximum recommended human dose. Also, the plasma concentrations of this metabolite measured in the in vivo genetic toxicity study, embryo-fetal development toxicity study, and carcinogenicity studies conducted with the parent drug provided adequate exposure and characterization of the metabolite. Therefore, no additional testing with the metabolite was needed.

Case 2.
Two primary hydroxylated metabolites, M1 and M2, were shown to undergo further oxidation to form secondary metabolites M3 and M4 using hepatic microsomes and hepatocytes from human, monkey, rat, dog, rabbit, and mouse. This metabolic profile was later confirmed by in vivo data. The results showed the following:

- M1 and M4 were the predominant metabolites in human, monkey, and dog microsomes, whereas rat, mouse, and rabbit formed M2 and M3
- M4 was formed in humans at 4-fold higher levels than the parent drug and 75 percent of the total drug-related exposure, but M4 was formed at very low levels in rodents and only represented 20 percent of the total drug-related exposure in monkey (see Table 1)

<table>
<thead>
<tr>
<th>Table 1: AUC_{0-24hr} at the Maximum Dose*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human (MRHD)*</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Total drug-related exposure</td>
</tr>
<tr>
<td>Parent Exposure</td>
</tr>
<tr>
<td>M4 Exposure</td>
</tr>
</tbody>
</table>

* AUC = area under the curve;  
MRHD = maximum recommended human dose

- Severe drug-related and novel target organ toxicities were observed with the parent drug in monkeys but not in rats
- M4 was pharmacologically inactive at the drug target receptors
The following additional studies were done with M4:

- Subchronic toxicity study: 3 months in rats
- Embryo-fetal development study in the rats
- In vitro genotoxicity testing: M4 was positive for point mutation and chromosomal aberration; the parent drug was negative
- Because of the positive genotoxicity, a carcinogenicity study that included M4 was recommended

**Case 3.**
M2 is a phase 1 oxidative metabolite that formed up to 50 percent of total drug-related exposure in humans, 10 percent of total drug-related exposure in mice, 15 percent of total drug-related exposure in dogs, and only trace amounts in rats. In vitro metabolism studies in these species supported the in vivo findings. Based on structure activity relationship analyses, there was no reason to anticipate any difference or exaggeration in toxicity of the metabolite compared with the parent molecule. The parent drug showed no significant toxicity or identifiable target organ of toxicity in any of the animal species tested in safety assessment studies. Because disproportionate human exposure was identified, further safety testing was needed. When M2 was tested in a short-term tolerance study in the dog, it produced unexpected and significant cardiotoxicity at all doses and in all of the dogs. M2 was pharmacologically inactive at the therapeutic target receptor.